Excision BioTherapeutics Announces Positive Preclinical Data Highlighting the Safety, Potency and Development Progress of the Hepatitis B EBT-107 Program at the ICE-HBV “Hepatitis B Cure Symposium”

Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced that positive preclinical data from its Hepatitis B virus (HBV) EBT-107 program were presented at the 6th ICE-HBV “HBV Cure Symposium” which took place on September 12, 2025, in Berlin, Germany.